Wortmannin

Catalog No.S2758 Synonyms: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • L3.6pl cells at 6,000 cells per well were incubated in MEM with 5% FBS in triplicate in a 96-well culture plate and then treated alone with 5 umol/L BMS-777607, 10 umol/L wortmannin, or with BMS-777607 in combination with individual inhibitors. Polyploidy was examined under BK71 Olympus microscope and photographed 72 hours after treatment.

    Mol Cancer Ther 2014 13(1), 37-48. Wortmannin purchased from Selleck.

    The effects of KITL on the differentiation of stem Leydig cells. Seminiferous tubules were cultured in the presence of various concentrations of KITL (K) without (C) or with PI3K inhibitor wortmannin (W) for 21 days. Panel A, KITL (0-100 ng/ml); Panel B, KITL (K) alone or with W (100 nM), K1 = KITL 1 ng/ml, K100 = 100 ng/ml. Medium testosterone (T) levels were measured. Mean ± SEM, n = 4-8. Identical letters indicate no significant difference between two groups at P < 0.05. W:Wortmannin

    Mol Cell Endocrinol, 2017, 444:1-8. Wortmannin purchased from Selleck.

  • Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

    Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

  • Cell growth inhibition of non-small cell lung carcinoma (NSCLC) by inhibitor of phosphoinositide 3-kinases (PI3Ks) Wortmannin. NCI-H460 and its multi-drug resistant (MDR) counterpart NCI-H460/R were subjected to Wortmannin. According to the results obtained, the effect of Wortmannin is dependent on the existence of MDR in the range of tested concentrations.

    2014 Dr.Milica Pesic from Institute for Biological Research. Wortmannin purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWqyMlUh|ryP NIHjSXIyNTRiZB?= MVnEUXNQ NWf1S4x[\W6qYX7j[ZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD0doVifG2nboSge4l1cCC2YX3vfIln\W5? NFnxeZIzPTR7MEO4Ny=>
H1703 M3;qdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWj5d5RLOi53IN88US=> MUKxMVQh\A>? M2\rfmROW09? MWDlcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKHS{ZXH0cYVvfCC5aYToJJRidW:6aX\lci=> NEHYTYkzPTR7MEO4Ny=>
HUVECs M4fuUmN6fG:2b4jpZ4l1gSCDc4PhfS=> M2\pN|ExOCCwTR?= M2m4VlI1KGh? M2HoWIF1fGWwdXH0[ZMhfGinIHHido9o[XSrdnWg[YZn\WO2czDv[kBk[Wy7Y3;zbY4hd25iVmLJMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 MkD5NlU1PTBzOE[=
APRE-19 MYHBdI9xfG:|aYOgRZN{[Xl? NX3tWWRLPSEQvF2= M1nlVlI1KGh? NUe0b|FI[WKxbHnzbIV{KE[OWj3t[YRq[XSnZDDwdo8ue3W{dnn2ZYww[W62aT3hdI9xfG:|aYOgZYN1cX[rdIm= M4PRVVI2OzJ7NkG3
MDA-MB-231 NY\2c4w6SXCxcITvd4l{KEG|c3H5 MluxNeKh|ryPwrC= M1nXT|Q5KGh? NYDoPGJlTE2VTx?= MXXk[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygeJJm[XSnZDD3bZRpKDJ3IN88UUBw\iCIMTDvdkBHOiEEoB?= NVrNcol4OjV|MEC5N|I>
MCF7 Mme5SpVv[3Srb36gRZN{[Xl? NITN[YkyODBibl2= NF\pWXkzPCCq M{PrZYVtcW2rbnH0[ZMhTTJvaX7keYNm\CCDUlWtUJVkKGGldHn2bZR6 MUeyOVE4OjV3Nx?=
HT-29  MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVWxMlXDqML3TR?= NWPQfIY5QTZiaB?= NFnzTXJl\WO{ZXHz[ZMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJIlvcGmkaYTl[EBjgSCNWV7B M1\CblI2ODF{MUKz
MO59K  NHT0WVVEgXSxdH;4bYNqfHliQYPzZZk> MUm1xsDPxE1? NEPxcVg4KGR? NVvJNI1HTE2VTx?= NHrBflZmdmijbnPld{B1cGViY4n0c5RwgGmlaYT5JI9nKGW2b4Dvd4ll\SCxcjDjbZNxdGG2aX6= NHjEeHMzPDl3M{W2NS=>
MO59J MXvDfZRwfG:6aXPpeJkhSXO|YYm= NETKSYU2yqEQvF2= M4LIOFch\A>? NI\Gc3hFVVOR M4\vOYVvcGGwY3XzJJRp\SCleYTveI95cWOrdImgc4Yh\XSxcH;zbYRmKG:{IHPpd5Bt[XSrbh?= MlGzNlQ6PTN3NkG=
MO59K  NVTUS|FpSXCxcITvd4l{KEG|c3H5 MoLINVAh|ryP NIf6SpkzPCCq NWLRW|A6TE2VTx?= NWjSS4pocW6lcnXhd4V{KHSqZTDEV2IhdGW4ZXygbY5lfWOnZDDifUBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw M3HQclI1QTV|NU[x
MO59J MXnBdI9xfG:|aYOgRZN{[Xl? NIfoc20yOCEQvF2= MmTUNlQhcA>? NYfsNGp2TE2VTx?= Mof1bY5kemWjc3XzJJRp\SCGU1KgcIV3\WxiaX7keYNm\CCkeTDleI9xd3OrZHWgc5Ih[2m|cHzheIlv MVKyOFk2OzV4MR?=
HepG2 NV;CVmxpTnWwY4Tpc44hSXO|YYm= MlXHNVAxKG6P NFXxN3ExNjViaB?= M3n3TWROW09? MlyzZoxw[2u|IF3BMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvci=> M{XDNFI1QDZ|M{Ww
A549  NIPpVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUezJOK2VcLi NFK5PYgzKGh? NIf3NZd{fXCycnXzd4V{KHCnbXX0doV5\WRvaX7keYNm\CCDa4SgZY5lKEeVS{ROtkBi[3SrdnH0bY9vNCCVLYDoZZNmKGG{cnXzeEwh[2WubDDhdI9xfG:|aYOgZY5lKGOjc4Dhd4UuOyCjY4TpeoF1cW:w NULqUVJWOjR6NEe4OlM>
A549  M{PZ[GZ2dmO2aX;uJGF{e2G7 NHH4fGoyOMLizsztxsA> MX6xOkBp M2nnS2ROW09? M16wbI1w\HWuYYTld{B1cGViSVHWJJJmeGyrY3H0bY9vKGGwZDDjZZV{\XNicnX0[Y51cW:wIH;mJG5RKGmwIITo[UBvfWOuZYXzMi=> NF\3NXczPDhyMkGxNS=>
SK-N-LO MULGeY5kfGmxbjDBd5NigQ>? NWL3PYFSOTByIH7N MmPTNE42KGh? M1S3[IRm[3KnYYPld{B1cGVic4TpcZVt[W62IHXm[oVkfHNib3[gcY9zeGirbnWgc44hSWu2IIDoc5NxcG:{eXzheIlwdg>? NV74O5VZOjR4NUS2NFY>
HL-60 MXXGeY5kfGmxbjDBd5NigQ>? M1LQNVAvOcLizszN M3H5T|czKGh? MoLvZoxw[2u|IHThd4F1cW6rYj3pcoR2[2WmIHPlcIwh\GmoZnXy[Y51cWG2aX;u MlH4NlQ3ODd{N{O=
HepG2  NX6wfIdNTnWwY4Tpc44hSXO|YYm= M3PzOlIxOCCwTR?= NHPxOG4xNjViaB?= MWXheJRmdnWjdHXzJGZwgE9icHjvd5Bpd3K7bHH0bY9v MYeyOFU{PTF7Mh?=
H520 M{Lnb2Z2dmO2aX;uJGF{e2G7 NHfWe|gyOMLizszN M17XZ|EhcA>? MljuSG1UVw>? M13Te4Rm[3KnYYPld{Bk\WyudXzhdkBxcG:|cHjvMWFMXCCycn;0[YlvKGyndnXsdy=> NXjoeoY2OjR2NEe5N|U>
H1975 NFfyTVlHfW6ldHnvckBCe3OjeR?= M1vBVVExyqEQvF2= M{HWVVEhcA>? MXfEUXNQ M2LId4Rm[3KnYYPld{Bk\WyudXzhdkBxcG:|cHjvMWFMXCCycn;0[YlvKGyndnXsdy=> MXWyOFQ1Pzl|NR?=
MG-63 NVLGSldZSXCxcITvd4l{KEG|c3H5 NFzIWG8yOCEEtV2= MlLCNVIhcA>? MUPlcohidmOnczDEVE1qdmS3Y3XkJIFxd3C2b4Ppdy=> M{LvVFI1OzV6M{Cx
5637 MkPwRZBweHSxc3nzJGF{e2G7 NUDTO406OTEEoN88US=> NHTCWog1OCCvaX6= MXjy[ZZmenOnczDwNlFYSUZzIHX4dJJme3Orb36sJGNFUyCneIDy[ZN{cW:wLDDhcoQh[2WubDDpcohq[mm2aX;uJIlv\HWlZXSgZpkh\nWlb3nkZY4> NIW3NHAzPDN|M{i2PC=>
HEK-293 MWLGeY5kfGmxbjDBd5NigQ>? MV[xOVBvVQ>? MVexOkBp M4HVNWROW09? MoL4[IVkemWjc3XzJGNTXCCjY4Tpeol1gQ>? MUGyOFMzPDN4Nh?=
SW480  NHq5cZhHfW6ldHnvckBCe3OjeR?= NVjDXXIxOTVybl2= NF71VVQzOCCq M2m3cGROW09? MV\y[YR2[2W|IHPlcIx2dGG{IHHjZ5VufWyjdHnvckBw\iEQsj3jZZRmdmmw MViyOFMzPDN4Nh?=
HepG2 M2XpU2Z2dmO2aX;uJGF{e2G7 NILmR5EyODBibl2= M2OzTlI1KGh? MUDheJRmdnWjdHXzJJRp\SClb3zvcolmeyCxZjD0bIUhfHWvb4KgZ4VtdHNid3n0bEB2eHKnZ4XsZZRqd25ib3[gRYt1OQ>? Mlu2NlQzQTd3MUC=
HCT 116  M{jldmZ2dmO2aX;uJGF{e2G7 NGHxdZQyODBibl2= NEDsbZkzPCCq NHvIfIZifHSnboXheIV{KHSqZTDjc4xwdmmnczDv[kB1cGVidIXtc5Ih[2WubIOge4l1cCC3cILl[5Vt[XSrb36gc4YhSWu2MR?= MX:yOFI6PzVzMB?=
BEL/FU NYTZSlVTTnWwY4Tpc44hSXO|YYm= M4f6RVEhdU1? MnfVNlQhcA>? MY\k[YNz\WG|ZYOgdJJwfGWrbjDs[ZZmdHNib3[geIhmKFCLM1uvRYt1KHCjdHj3ZZk> NEHYSIQzPDJ|MkC5PS=>
Huh7  NYntVZAyTnWwY4Tpc44hSXO|YYm= M1zPfVPDqM7:TR?= NXLRPVdKOSCq NUiyN5QzemWmdXPld{B1cGVidnnyeZMh\W62comgbY51dyC2aHWgZ4VtdHN? MnTKNlQyQDRzOU[=
A-375 M33nXWFxd3C2b4Ppd{BCe3OjeR?= MU[0M|gh|ryP NF3hR4UzPCCq NXj0e4xM\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> MU[yOFEyOzF5Mx?=
A-375-TS  Mn75RZBweHSxc3nzJGF{e2G7 MYq0M|gh|ryP NED1XnQzPCCq M17zZ4VvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= NH30U|kzPDFzM{G3Ny=>
Mel-HO M1fZeGFxd3C2b4Ppd{BCe3OjeR?= Mnn3OE85KM7:TR?= M1PYbVI1KGh? MlTY[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= NF7kTGEzPDFzM{G3Ny=>
Mel-HO-TS NFLJboFCeG:ydH;zbZMhSXO|YYm= Mnu3OE85KM7:TR?= MkO4NlQhcA>? MoXw[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= NEjudJMzPDFzM{G3Ny=>
MeWo NXjhSGtISXCxcITvd4l{KEG|c3H5 NIrSNXc1NzhizszN NH3Ffo8zPCCq NVLFZWlK\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> MoTnNlQyOTNzN{O=
Mel-2a MkHERZBweHSxc3nzJGF{e2G7 Ml32OE85KM7:TR?= Mo\NNlQhcA>? MoLN[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= M33iV|I1OTF|MUez
MDA-MB-231 MUTGeY5kfGmxbjDBd5NigQ>? M1;afVDjiJN2MECgcm0> NIXsdHo1KGh? MmX0d5VxeHKnc4Pld{BCc3RicHjvd5Bpd3K7bHH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2jsblIzQTB4MkW5
MDA-MB-231 NHzPbotHfW6ldHnvckBCe3OjeR?= NVX3SnlrPDByIH7N NESzRWI1KGh? NH3FPZRl\WO{ZXHz[ZMhVU2SLUmgZY5lKEmOLUigdJJwfGWrbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mk\nNlI6ODZ{NUm=
Jurkat MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTHXmx1OC5{NT2xMlI2KM7:TR?= MVuyOE81QCCq MXHEUXNQ NEjOWJFqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= MWexPVc2PzF6NR?=
Namalwa NIrGe41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2j2e|AvOjVvMT6yOUDPxE1? MV:yOE81QCCq NHj3SJpFVVOR NXWyUW53cW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= MVSxPVc2PzF6NR?=
Jurkat M2HifmFxd3C2b4Ppd{BCe3OjeR?= NHrDfocxNjJ3LUGuNlUh|ryP MVqyOE81QCCq NVu2bY9KTE2VTx?= NVy1UWJ3cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz Ml;vNVk4PTdzOEW=
Namalwa MV\BdI9xfG:|aYOgRZN{[Xl? MmnDNE4zPS1zLkK1JO69VQ>? NFLWXI0zPC92ODDo NH\WNlBFVVOR NFL6bJRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI> NWjHOmtGOTl5NUexPFU>
K562 NIPiXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCyOEBp M3nqS2lEPTB;MkZCtVAvOTRibl2= M4q0VVE6PjZ{M{[x
SW1990 NHfYU2NHfW6ldHnvckBCe3OjeR?= MV:wMlAyNTFizszN NInlXW0yKGh? Ml[wbY5pcWKrdIOgTGEucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9v M3rUS|E6PDZ7MEKw
RT112  NID4OWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7zdXQ4OTEEoN88US=> NGXnWYkzPCCq M{S3S2ROW09? NGfLPZdl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4YhTzJxTTDj[Yxtew>? MXOxPFc5Pzh|Mh?=
MHG-U1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW5NVDDqM7:TR?= M{LYflI1KGh? NXO2WlZuTE2VTx?= NELnPWdl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4YhTzJxTTDj[Yxtew>? MVGxPFc5Pzh|Mh?=
SMMC-7721 NUXNWHZNSXCxcITvd4l{KEG|c3H5 MkfwNlAxyqCwTR?= Mnz1NlQhcA>? Ml;abY5kemWjc3XzJGNJYC2rbnT1Z4VlKGGyb4D0c5Nqew>? M{nSblE4PTV5MUmx
SMMC-7721 NY\nO242TnWwY4Tpc44hSXO|YYm= NEXQPW0zODEEoH7N NELPTmkzPCCq MWX1dE1z\We3bHH0[ZMh|rJzLETHWFEh\XiycnXzd4lwdg>? M3ztTVE4PTV5MUmx
HeLa NWTMUXJLTnWwY4Tpc44hSXO|YYm= M2G0dFExOMLibl5CpC=> NFvEVYcyKGh? MmDVZYx1\XK|IITo[UBud3KyaH;sc4d6KG:oIITo[UB1emGwc3\ldpJqdiC{ZXP5Z4xqdmdiY3;tdIFzfG2nboS= MmqwNVY5QTB7MUW=
MRC5VI MUDGeY5kfGmxbjDBd5NigQ>? NGftenMyOi53IH3N NWSzTmgyOC53IHi= NI[1OW9FVVOR MY\hZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> MmWyNVYzOjd|OUS=
AT5BIVA MWHGeY5kfGmxbjDBd5NigQ>? MXuxNk42KG2P NX\KWlNUOC53IHi= MVrEUXNQ NFTRN5Bi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? NGLsc44yPjJ{N{O5OC=>
M059J NGHFfFVHfW6ldHnvckBCe3OjeR?= M13EZ|EzNjVibV2= NXLqOYFXOC53IHi= MmD4SG1UVw>? MX3hZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> NUPXWJpJOTZ{MkezPVQ>
HeLa MmX1SpVv[3Srb36gRZN{[Xl? NVmyUWRYOTJwNTDtUS=> MWmwMlUhcA>? MXXEUXNQ NWjNT3Z4[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? NX7IVVQ5OTZ{MkezPVQ>
N2a M2HFTWFxd3C2b4Ppd{BCe3OjeR?= NFnObnMxNjFvMUCg{txO NXXmXIU1OiCq NGfjZphqdmS3Y3XzJIRm[3KnYYPl[EBk\WyuII\pZYJqdGm2eTDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?= NF35cpMyPTh2Mke2Oy=>
Jurkat  MXfLbY5ie2ViQYPzZZk> MXLJR|UxKG:oIEK0JI5O NIX3O3cyPTZ4NEWxPS=>

... Click to View More Cell Line Experimental Data

In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
+ Expand
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
in solvent
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID